Welcome to our dedicated page for Horizon Therapeutics Plc news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.
Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.
Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.
Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.
For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Horizon Therapeutics (Nasdaq: HZNP) presented vital information on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology from June 19-22, 2021. Key presentations included long-term safety and efficacy outcomes from the N-MOmentum trial and insights into immunoglobulin kinetics and infection risk. NMOSD is a severe autoimmune disease that necessitates ongoing management, affecting primarily women and individuals of African and Asian descent.
Horizon Therapeutics (Nasdaq: HZNP) announced its agreement to acquire a drug manufacturing facility from EirGen Pharma in Waterford, Ireland, for $65 million. The facility will enhance Horizon's in-house manufacturing capabilities for its rare disease biologics, including TEPEZZA and KRYSTEXXA. Plans are in place to work with regulatory agencies for necessary approvals, with the first product expected to be released in about two years. The acquisition will also include the transfer of approximately 40 employees and plans to recruit an additional 50 staff members by 2022.
Horizon Therapeutics (Nasdaq: HZNP) presented new data from the PROTECT study at the EULAR European Congress of Rheumatology, focusing on the efficacy of KRYSTEXXA (pegloticase) for treating uncontrolled gout in kidney transplant patients. The ongoing Phase 4 trial maintains stable kidney function and shows promising safety results. Among 10 patients, the mean eGFR improved from 41.6 to 43.8 mL/min/1.73 m². Patients reported significant reductions in pain and disability. The trial was fully enrolled in January 2021 and is expected to conclude in Fall 2021.
Horizon Therapeutics plc (Nasdaq: HZNP) announced the enrollment of the first patient in the ADVANCE trial, which examines the use of KRYSTEXXA (pegloticase injection) combined with methotrexate for patients with uncontrolled gout who did not respond to KRYSTEXXA alone. This open-label trial aims to enroll 30 patients and has a primary endpoint of maintaining serum uric acid levels below 6 mg/dL for at least 80% of Month 6. The safety and efficacy of this combined treatment are yet to be established by health authorities.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in two upcoming conferences: the Jefferies Virtual Health Care Conference on June 3, 2021, at 1 p.m. ET, and the BMO Biopharma Day on June 22, 2021, at 10 a.m. ET. Live webcasts of both presentations can be accessed on Horizon's website, with replays available afterward. Horizon focuses on developing medicines for rare, autoimmune, and severe inflammatory diseases, emphasizing a commitment to impactful therapies for patients.
Horizon Therapeutics plc (Nasdaq: HZNP) announced its data presentations at the EULAR European Congress of Rheumatology from June 2-5, 2021. The company will present findings on HZN-4920 (VIB4920), targeting rheumatoid arthritis, alongside updates on the PROTECT trial concerning KRYSTEXXA (pegloticase injection) for chronic gout patients, including those who have undergone kidney transplants. Horizon is committed to enhancing research in rheumatic diseases to inform treatment strategies and improve patient outcomes.
Horizon Therapeutics plc (Nasdaq: HZNP) ranked #1 in overall corporate reputation among U.S. patient groups that worked with the company, and #2 among those familiar with it, according to PatientView's annual survey of 207 patient groups evaluating 38 pharmaceutical companies. Horizon excelled in supporting patients during the COVID pandemic and demonstrating integrity, transparency, and effective patient-centered strategy. Globally, Horizon ranked #2 in overall reputation and top in multiple categories, reaffirming its commitment to improving lives through advocacy and partnerships.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in the Bank of America Securities 2021 Health Care Conference on May 11, 2021. The presentation is scheduled for 3:30 p.m. ET and will be available for live streaming on Horizon's website. A replay will also be accessible after the event. Horizon is dedicated to developing medicines for rare, autoimmune, and severe inflammatory diseases, emphasizing a combination of scientific innovation and compassion. For more details, visit www.horizontherapeutics.com.
Horizon Therapeutics plc (Nasdaq: HZNP) announced new findings from the Phase 2/3 N-MOmentum trial for UPLIZNA, revealing its potential to reduce worsening disability in NMOSD patients. Published in the May issue of Neurology Neuroimmunology & Neuroinflammation, these results underline UPLIZNA's role as the first FDA-approved anti-CD19 B-cell depleting therapy for NMOSD. Additionally, a separate analysis points to serum glial fibrillary acidic protein (sGFAP) as a novel biomarker for assessing disease activity in NMOSD, addressing limitations in current monitoring methods.
FAQ
What is Horizon Therapeutics?
What products does Horizon Therapeutics offer?
What recent achievements has Horizon Therapeutics made?
Who is acquiring Horizon Therapeutics?
How is Horizon Therapeutics contributing to medical science?
What is the mission of Horizon Therapeutics?
How can I learn more about Horizon Therapeutics?
What is the significance of Horizon’s recent agreement with the FTC?
Where is Horizon Therapeutics headquartered?
What is the focus of Horizon's research and development efforts?
